PMID- 24772386
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 2213-4344 (Print)
IS  - 2213-4344 (Electronic)
IS  - 2213-4344 (Linking)
VI  - 2
IP  - 2
DP  - 2014 Apr 1
TI  - Detection and Treatment of Long-Chain Omega-3 Fatty Acid Deficiency in 
      Adolescents with SSRI-Resistant Major Depressive Disorder.
PG  - 38-46
AB  - Residual depressive symptoms are commonly observed in adolescents with major 
      depressive disorder (MDD) following treatment with selective serotonin reuptake 
      inhibitors (SSRIs). This study combined a case-control analysis and an open-label 
      fish oil (FO) trial to investigate the relationship between long-chain omega-3 
      (LCn-3) fatty acid status and residual depressive symptoms in SSRI-resistant 
      adolescent MDD patients. Baseline erythrocyte docosahexaenoic acid (DHA)(-28%, 
      p=0.0003), but not eicosapentaenoic acid (EPA)(-18%, p=0.2), was significantly 
      lower in patients (n=20) compared with healthy controls (n=20). Patients 
      receiving 10-week low-dose (2.4 g/d, n=7) and high-dose (16.2 g/d, n=7) FO 
      exhibited significant increases in erythrocyte EPA and DHA composition. In the 
      intent-to-treat sample, depressive symptoms decreased significantly in the 
      high-dose group (n=7, -40%, p<0.0001), and there was a trend in the low-dose 
      group (n=10, -20%, p=0.06). Symptom remission was observed in 40% of patients in 
      the low-dose group and 100% of patients in the high-dose group. There were no 
      significant changes in vital signs and adverse events were rated as mild or 
      moderate in severity. These preliminary findings demonstrate that adolescents 
      with SSRI-resistant depression exhibit robust DHA deficits, and suggest that 
      adjunctive FO supplementation is well-tolerated and effective for increasing 
      LCn-3 fatty acid status and augmenting SSRI antidepressant effects.
FAU - McNamara, Robert K
AU  - McNamara RK
AD  - Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati 
      College of Medicine, Cincinnati OH 45219.
FAU - Strimpfel, Jennifer
AU  - Strimpfel J
AD  - Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati 
      College of Medicine, Cincinnati OH 45219.
FAU - Jandacek, Ronald
AU  - Jandacek R
AD  - Department of Pathology, University of Cincinnati, Cincinnati OH 45237.
FAU - Rider, Therese
AU  - Rider T
AD  - Department of Pathology, University of Cincinnati, Cincinnati OH 45237.
FAU - Tso, Patrick
AU  - Tso P
AD  - Department of Pathology, University of Cincinnati, Cincinnati OH 45237.
FAU - Welge, Jeffrey A
AU  - Welge JA
AD  - Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati 
      College of Medicine, Cincinnati OH 45219.
FAU - Strawn, Jeffrey R
AU  - Strawn JR
AD  - Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati 
      College of Medicine, Cincinnati OH 45219.
FAU - Delbello, Melissa P
AU  - Delbello MP
AD  - Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati 
      College of Medicine, Cincinnati OH 45219.
LA  - eng
GR  - R01 DK097599/DK/NIDDK NIH HHS/United States
GR  - U24 DK059630/DK/NIDDK NIH HHS/United States
GR  - U2C DK059630/DK/NIDDK NIH HHS/United States
GR  - UL1 TR001425/TR/NCATS NIH HHS/United States
PT  - Journal Article
PL  - Netherlands
TA  - PharmaNutrition
JT  - PharmaNutrition
JID - 101602522
PMC - PMC3998067
MID - NIHMS574062
OTO - NOTNLM
OT  - Adolescents
OT  - Docosahexaenoic acid
OT  - Eicosapentaenoic acid
OT  - Erythrocyte
OT  - Major depressive disorder (MDD)
OT  - Omega-3 fatty acids
EDAT- 2014/04/29 06:00
MHDA- 2014/04/29 06:01
PMCR- 2015/04/01
CRDT- 2014/04/29 06:00
PHST- 2014/04/29 06:00 [entrez]
PHST- 2014/04/29 06:00 [pubmed]
PHST- 2014/04/29 06:01 [medline]
PHST- 2015/04/01 00:00 [pmc-release]
AID - 10.1016/j.phanu.2014.02.002 [doi]
PST - ppublish
SO  - PharmaNutrition. 2014 Apr 1;2(2):38-46. doi: 10.1016/j.phanu.2014.02.002.